Literature DB >> 24711129

Increased rates of periprosthetic joint infection in patients with cirrhosis undergoing total joint arthroplasty.

Shirley L Jiang1, William W Schairer, Kevin J Bozic.   

Abstract

BACKGROUND: Total joint arthroplasty (TJA) is becoming more prevalent, with additional increases in procedure rates expected as the US population ages. Small series have suggested increased risk of periprosthetic joint infections in patients with liver cirrhosis after TJA. However, the rates of periprosthetic joint infections and use of TJA for patients with cirrhosis have not been evaluated on a larger scale. QUESTIONS/PURPOSES: The purposes of this study were to (1) measure the rate of periprosthetic joint infections after THAs and TKAs in patients with cirrhosis of the liver; (2) assess mortality, length of hospital stay, readmission rates, and other clinical factors among patients with cirrhosis who have had a TJA; and (3) evaluate the use of TJA in the United States among patients with liver cirrhosis during the past decade.
METHODS: National and state-level databases were used to identify patients with and without liver cirrhosis who underwent TJAs. The rate of periprosthetic joint infections within 6 months was assessed using the Statewide Inpatient Database, which identified 306,946 patients undergoing THAs (0.3% with cirrhosis) and 573,840 patients undergoing TKAs (0.2% with cirrhosis). To evaluate trends in the use of TJAs, 16,634 patients with cirrhosis who underwent TJAs were identified from the Nationwide Inpatient Sample from 2000 to 2010.
RESULTS: Periprosthetic joint infections after THA were more common in patients with cirrhosis for hip fracture (6.3% versus 1.1%; hazard ratio [HR], 5.8; p < 0.001) and nonhip fracture diagnoses (3.7% versus 0.7%; HR, 5.4; p < 0.001). Periprosthetic joint infections were more common after TKA in patients with cirrhosis (2.7% versus 0.8%; HR, 3.4; p < 0.001). Use of TJA increased faster for patients with cirrhosis than for patients without cirrhosis for THAs (140% versus 80%; p = 0.011) and TKAs (213% versus 128%; p < 0.001), and also increased faster than the general increase in use of TJAs.
CONCLUSIONS: Periprosthetic joint infections were more common among patients with cirrhosis who had TJAs. Additionally, patients with cirrhosis had longer length of hospital stay, increased costs, and higher rates of mortality, readmission, and reoperation. Finally, national use of TJAs for patients with cirrhosis has increased during the past decade. LEVEL OF EVIDENCE: Level III, therapeutic study. See the Instructions for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2014        PMID: 24711129      PMCID: PMC4079852          DOI: 10.1007/s11999-014-3593-y

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  28 in total

1.  Advanced age and comorbidity increase the risk for adverse events after revision total hip arthroplasty.

Authors:  Karl Koenig; James I Huddleston; Heather Huddleston; William J Maloney; Stuart B Goodman
Journal:  J Arthroplasty       Date:  2012-01-14       Impact factor: 4.757

2.  One-stage bilateral total joint arthroplasty: a prospective, comparative study of total hip and total knee replacement.

Authors:  E Louis Peak; William J Hozack; Peter F Sharkey; Javad Parvizi; Richard H Rothman
Journal:  Orthopedics       Date:  2008-02       Impact factor: 1.390

3.  Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002.

Authors:  Steven Kurtz; Fionna Mowat; Kevin Ong; Nathan Chan; Edmund Lau; Michael Halpern
Journal:  J Bone Joint Surg Am       Date:  2005-07       Impact factor: 5.284

4.  The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization.

Authors:  Kevin J Bozic; Michael D Ries
Journal:  J Bone Joint Surg Am       Date:  2005-08       Impact factor: 5.284

5.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

6.  Prosthetic hip infection in patients with liver cirrhosis: an outcome analysis.

Authors:  Pang-Hsin Hsieh; Steve W Ueng; Mel S Lee; Hsin-Nung Shih; Kuo-Chin Huang
Journal:  Int J Infect Dis       Date:  2010-10-08       Impact factor: 3.623

7.  A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.

Authors:  R W Chang; J M Pellisier; G B Hazen
Journal:  JAMA       Date:  1996-03-20       Impact factor: 56.272

Review 8.  Outcomes of patients with cirrhosis undergoing non-hepatic surgery: risk assessment and management.

Authors:  Farida Millwala; Geoffrey C Nguyen; Paul J Thuluvath
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

9.  Fibrosis in hepatitis C patients predicts complications after elective total joint arthroplasty.

Authors:  Fabio Orozco; Zachary D Post; Omkar Baxi; Adam Miller; Alvin Ong
Journal:  J Arthroplasty       Date:  2013-05-04       Impact factor: 4.757

10.  Perioperative risk of hip arthroplasty in patients with cirrhotic liver disease.

Authors:  Young-Wan Moon; Yong-Sik Kim; Soon-Yong Kwon; Shin-Yoon Kim; Seung-Jae Lim; Youn-Soo Park
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

View more
  16 in total

Review 1.  Factors That Affect Outcome Following Total Joint Arthroplasty: a Review of the Recent Literature.

Authors:  Forrest H Schwartz; Jeffrey Lange
Journal:  Curr Rev Musculoskelet Med       Date:  2017-09

2.  Are high-risk patient and revision arthroplasty effective indications for closed-incisional negative-pressure wound therapy after total hip or knee arthroplasty? A systematic review and meta-analysis.

Authors:  Jun-Ho Kim; Dae-Hee Lee
Journal:  Int Wound J       Date:  2020-05-13       Impact factor: 3.315

3.  Impact of Cirrhosis on Resource Use and Inpatient Complications in Patients Undergoing Total Knee and Hip Arthroplasty.

Authors:  Jared M Newman; Nicholas K Schiltz; Christopher D Mudd; Caleb R Szubski; Alison K Klika; Wael K Barsoum
Journal:  J Arthroplasty       Date:  2016-04-27       Impact factor: 4.757

4.  Impact of Cirrhosis on Morbidity and Mortality After Spinal Fusion.

Authors:  Young Lu; Charles C Lin; Hayk Stepanyan; Andrew P Alvarez; Nitin N Bhatia; P Douglas Kiester; Charles D Rosen; Yu-Po Lee
Journal:  Global Spine J       Date:  2019-10-10

5.  Outcomes of Patients With Cirrhosis Undergoing Orthopedic Procedures: An Analysis of the Nationwide Inpatient Sample.

Authors:  Neehar D Parikh; Yu-Hui Chang; Elliot B Tapper; Amit K Mathur
Journal:  J Clin Gastroenterol       Date:  2019-10       Impact factor: 3.062

Review 6.  Identifying Risk Factors Associated With Postoperative Infection Following Elective Lower-Extremity Total Joint Arthroplasty.

Authors:  Michelle Lespasio; Michael Mont; Anthony Guarino
Journal:  Perm J       Date:  2020-12

Review 7.  Patient, Surgery, and Hospital Related Risk Factors for Surgical Site Infections following Total Hip Arthroplasty.

Authors:  Georgios Triantafyllopoulos; Ottokar Stundner; Stavros Memtsoudis; Lazaros A Poultsides
Journal:  ScientificWorldJournal       Date:  2015-05-14

8.  Cirrhosis is a risk factor for total hip arthroplasty for avascular necrosis.

Authors:  Thomas Deleuran; Søren Overgaard; Hendrik Vilstrup; Peter Jepsen
Journal:  Acta Orthop       Date:  2016-02-22       Impact factor: 3.717

9.  Predicting lower limb periprosthetic joint infections: A review of risk factors and their classification.

Authors:  David A George; Lorenzo Drago; Sara Scarponi; Enrico Gallazzi; Fares S Haddad; Carlo L Romano
Journal:  World J Orthop       Date:  2017-05-18

10.  Failure to Medically Optimize Before Total Hip Arthroplasty: Which Modifiable Risk Factor Is the Most Dangerous?

Authors:  Joseph M Statz; Susan M Odum; Nicholas R Johnson; Jesse E Otero
Journal:  Arthroplast Today       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.